As obesity pharmacotherapy rapidly advances, tirzepatide and semaglutide now stand among the most clinically significant incretin-based treatments available
GLP-1R agonist therapy for diabetes: benefits and potential risks
Safety, side effects, and clinical oversight The FDA-labeled side-effect profile for GLP-1 receptor agonists and the GIP/GLP-1 dual agonist tirzepatide is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common
Anti-aging research - investigated for its involvement in reducing oxidative stress markers and improving skin density and elasticity
GcgR adds hepatic fat mobilization and thermogenesis not seen with dual agonists
Take a daily multivitamin 2 hours apart from orlistat